<DOC>
	<DOCNO>NCT00003339</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's cancer cell may make body build immune response kill tumor cell . Interleukin-12 may kill tumor cell stop blood flow tumor stimulate white blood cell kill melanoma cell . PURPOSE : Randomized phase II trial determine effectiveness vaccine therapy give interleukin-12 treating patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy With Without Interleukin-12 Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate immune reactivity tyrosinase gp100 peptide emulsify Montanide ISA-51 ( ISA-51 ) without interleukin-12 follow surgical resection HLA-A2 positive patient stage III IV melanoma . OUTLINE : This randomize , parallel study . Patients stratify prior therapy ( immunotherapy chemotherapy v surgery ) . Patients randomize receive 1 2 treatment arm : Arm I : Following surgery , patient receive tyrosinase gp100 peptide emulsify Montanide ISA-51 ( ISA-51 ) subcutaneously ( SQ ) weekly week 0 , 2 , 4 , 6 , 10 , 14 , 18 , 26 total 8 vaccination . Arm II : Following surgery , patient receive treatment Arm I follow interleukin-12 SQ weekly week 0 , 2 , 4 , 6 , 10 , 14 , 18 , 26 total 8 vaccination . Patients follow 2-4 week , every 3 month 2 year resection , every 6 month 3 year , yearly without evidence disease . PROJECTED ACCRUAL : A total 45 patient accrue study 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage III IV cutaneous ocular melanoma completely resect rendered free disease high risk recurrence OR Recurrent disease follow interferon alfa ineligible refuse interferon alfa HLAA2 positive Tumor tissue must available analysis gp100/tyrosinase expression Detectable expression one antigen require PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Absolute granulocyte count least 1,500/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2 mg/dL Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No major cardiovascular illness Pulmonary : No major respiratory illness ( e.g. , pneumonia ) Gastrointestinal : No major gastrointestinal illness Other : Not pregnant nursing No major systemic infection ( e.g. , sepsis ) No coagulation bleed disorder HIV negative Hepatitis B surface antigen negative Hepatitis C surface antigen negative No history uveitis autoimmune inflammatory eye disease No active autoimmune disease Not allergic Montanide ISA51 No active second malignancy within past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 1 month since prior biologic therapy Chemotherapy : At least 1 month since prior chemotherapy , include adjuvant therapy Endocrine therapy : At least 1 month since prior endocrine therapy No concurrent steroid therapy Radiotherapy : At least 1 month since prior radiotherapy Surgery : See Disease Characteristics At least 1 month since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>